

CLAIMS

1. An antibody or antigen-binding fragment thereof which binds to human IL-13, comprising:
 - (a) a light chain variable region comprising:
 - i. a CDR-L1 comprising SEQ ID NO:1,
 - ii a CDR-L2 comprising SEQ ID NO:2, and
 - iii a CDR-L3 comprising SEQ ID NO:3;
 - and
 - (b) a heavy chain variable region comprising:
 - i. a CDR-H1 comprising SEQ ID NO:4,
 - ii a CDR-H2 comprising SEQ ID NO:5, and
 - iii a CDR-H3 comprising SEQ ID NO:6.
2. An antibody or antigen-binding fragment according to claim 1, wherein the light chain variable region comprises the sequence given in SEQ ID NO:13 or SEQ ID NO:17.
3. An antibody or antigen-binding fragment according to claim 1 or claim 2, wherein the heavy chain variable region comprises the sequence given in SEQ ID NO:14 or SEQ ID NO:18.
4. An antibody or antigen-binding fragment according to any of claims 1 to 3, wherein the light chain variable region comprises the sequence given in SEQ ID NO:13 and the heavy chain variable region comprises the sequence given in SEQ ID NO:14, or sequences which are at least 95% identical thereto.
5. An antibody or antigen-binding fragment according to any of claims 1 to 3, wherein the light chain variable region comprises the sequence given in SEQ ID NO:17 and the heavy chain variable region comprises the sequence given in SEQ ID NO:18, or sequences which are at least 95% identical thereto.
6. An antibody or antigen-binding fragment according to claim 4 or claim 5, wherein the CDR-L1/CDR-L2/CDR-L3/CDR-H1/CDR-H2/CDR-H3 sequences comprise SEQ ID

NOs: 1/2/3/4/5/6 and the remainder of the light chain and heavy chain variable regions have at least 95% identity to SEQ ID Nos: 13 and 14 or SEQ ID NOs: 17 and 18 respectively.

7. An antibody or antigen-binding fragment according to any preceding claim, wherein the antibody is a chimeric, humanised or fully human antibody.
8. An antibody or antigen-binding fragment according to any of claims 1 to 6, wherein the antibody is a full-length antibody.
9. An antibody or antigen-binding fragment according to any of claims 1 to 6, wherein the antigen-binding fragment is a Fab, Fab', F(ab')₂, Fv, dsFv, scFv, or dsscFv.
10. An antibody or antigen-binding fragment according to claim 9, wherein the antigen-binding fragment is a scFv comprising the sequence given in SEQ ID NO:21 or a dsscFv comprising the sequence given in SEQ ID NO:23.
11. An isolated polynucleotide encoding an antibody or antigen-binding fragment according to any of claims 1 to 10.
12. An expression vector carrying the polynucleotide of claim 11.
13. A host cell comprising the vector as defined in claim 12.
14. A method of producing the antibody or antigen-binding fragment of any of claims 1 to 10, comprising culturing the host cell of claim 13 under conditions permitting production of the antibody or antigen-binding fragment, and recovering the antibody or antigen-binding fragment produced.
15. A pharmaceutical composition comprising an antibody or antigen-binding fragment as defined in any of claims 1 to 10, and a pharmaceutically acceptable adjuvant or carrier.

16. An antibody or antigen-binding fragment as defined in any of claims 1 to 10, or a pharmaceutical composition as defined in claim 15, for use in a method of treatment of the human or animal body by therapy.
17. The antibody, antigen-binding fragment or pharmaceutical composition according to claim 16, for use in the treatment of atopic dermatitis, chronic hand eczema, nasal micropolyposis or polyposis, food allergy, or eosinophilic esophagitis.
18. A method of treating or preventing atopic dermatitis, chronic hand eczema, nasal micropolyposis or polyposis, food allergy, or eosinophilic esophagitis, comprising administering a therapeutically effective amount of an antibody or antigen-binding fragment as defined in any of claims 1 to 10, or a pharmaceutical composition as defined in claim 15, to a patient in need thereof.